semaglutide cause heart problems in Cardiometabolic Diseases: SELECTing the Target Population Evaluating the Cardiovascular Benefits of

There were no unexpected safety findings at the Phase 2 stage that would fundamentally alter the risk-benefit profile expected for this class

Many patients report that their desire for alcohol and other substances diminishes or disappears on GLP-1s

Building or maintaining muscle requires progressive resistance that stimulates adaptation

Epicardial adipose tissue and coronary artery calcification in psoriasis patients

Clinical trial data suggests tirzepatide produces greater average weight loss than semaglutide, largely because it activates both the GLP-1 and GIP receptors rather than just GLP-1

For Longevity and HRT, Effecty ships nationwide